Brief: Dogwood Therapeutics Announces Low Dose IMC-2 Treatment
18/11/2024 14:03
Nov 18 (Reuters) - Dogwood Therapeutics Inc DWTX.O :
* DOGWOOD THERAPEUTICS, INC. ANNOUNCES LOW DOSE IMC-2
TREATMENT
REDUCES LONG-COVID RELATED FATIGUE AND SLEEP DISTURBANCE IN AN
INVESTIGATOR-INITIATED STUDY
* DOGWOOD THERAPEUTICS INC - IMC-2 SHOWS ROBUST REDUCTION IN
FATIGUE
Source text: ID:nGNX5DvX00
Further company coverage: DWTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study